T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer
Should dual HER2 blockade plus nab-paclitaxel be considered for neoadjuvant treatment of HER2+ breast cancer?Breast Cancer Research
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)–targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients with receptor-positive breast cancer subtypes. Preclinical discoveries are needed to identify, develop, and advance new drug targets to improve outcomes for patients with TNBC. Here, we report that MYCN, an oncogene typically overexpressed in tumors of the nervous system or with neuroendocrine features, is heterogeneously exp...
Condition: Mammary Cancer Interventions: Drug: Pertuzumab and trastuzumab FDC subcutaneous; Drug: Paclitaxel; Drug: TDM1; Drug: Endocrine therapy; Procedure: Omission surgery Sponsors: David Garcia Cinca; Fundacion Clinic per a la Recerca Biomédica Not yet recruiting
Conclusion: Tau protein expression can predict pCR before NACT in TNBC, but there was no correlation between Tau expression and DFS or OS. PMID: 32140269 [PubMed]
ConclusionsAddition of carboplatin to neoadjuvant chemotherapy significantly improved DFS and OS in patients with TNBC but not in those with hormone receptor-positive, HER2-negative breast cancer.
Condition: Early Breast Cancer Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Taxane; Drug: Letrozole; Drug: Abemaciclib; Drug: LHRH Analogue Sponsors: Spanish Breast Cancer Research Group; Eli Lilly and Company Not yet recruiting